Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Vera Therapeutics, Inc.NASDAQ: VERA
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses declines year over year
Q2 FY2026 other income / expenses of $3.02M fell 16.4% year over year, ahead of the -22.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 26.4% from the prior quarter. Over 3 fiscal years it compounded at +104.7% a year.
Context
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -16.4% holds above the trailing-twelve-month pace of -22.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 15.86M USD
- Year-over-year change
- +5.6%
- 4-year CAGR
- +72.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.86M | +5.6% |
| FY2024 | 2024-12-31 | 15.02M | +149.4% |
| FY2023 | 2023-12-31 | 6.02M | +225.9% |
| FY2022 | 2022-12-31 | 1.85M | +3.0% |
| FY2021 | 2021-12-31 | 1.79M | — |
Other Income / Expenses vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 other income / expenses of $13.87M is the 3rd highest of the 10 companies compared; the peer median is $7.39M.
- Its year-over-year change of -22.0% is the 5th highest of 10, against a peer median of -51.5%.
- Over three fiscal years its annual growth of +104.7% compares with a peer median of +158.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.94M | +1139.2% | +133.2% | 9870.5% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $18.29M | -91.0% | +350.3% | 247.2% |
| LTM Jun 2026 | $13.87M | -22.0% | +104.7% | — | |
| LTM Mar 2026 | $10.82M | -0.5% | +57.2% | 129.3% | |
| LTM Mar 2026 | $8.98M | -61.4% | +194.6% | — | |
| LTM Mar 2026 | $7.39M | -51.5% | +158.9% | — | |
| LTM Mar 2026 | -$3.5M | +18.6% | — | 0.9% | |
| LTM Jun 2026 | -$4.96M | +23.6% | — | 1.1% | |
| LTM Jun 2026 | -$18.16M | -151.5% | — | — | |
| LTM Mar 2026 | -$67.43M | -67.3% | — | 29.0% | |
| Peer median (excluding VERA) | $7.39M | -51.5% | +158.9% | 79.2% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.